Email UpdatesSAMHSA recognizes the challenges posed by the current COVID-19 situation and is providing the following guidance on the provision of methadone and buprenorphine for the treatment of Opioid Use Disorder in the COVID-19 emergency for Opioid Treatment Programs.
Source
Substance Abuse and Mental Health Services Administration
File Size
201 KB
Year
Format
Terms of Use
Resource Type
Special Collection